CN102430013A - 治疗白癜风的中药 - Google Patents
治疗白癜风的中药 Download PDFInfo
- Publication number
- CN102430013A CN102430013A CN2011104036920A CN201110403692A CN102430013A CN 102430013 A CN102430013 A CN 102430013A CN 2011104036920 A CN2011104036920 A CN 2011104036920A CN 201110403692 A CN201110403692 A CN 201110403692A CN 102430013 A CN102430013 A CN 102430013A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- chinese medicine
- medicine
- fructus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 58
- 238000000034 method Methods 0.000 claims abstract description 11
- 241000190633 Cordyceps Species 0.000 claims description 13
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 13
- 241000522620 Scorpio Species 0.000 claims description 13
- 238000005516 engineering process Methods 0.000 claims description 13
- 238000002360 preparation method Methods 0.000 claims description 13
- 210000000582 semen Anatomy 0.000 claims description 13
- 229940079593 drug Drugs 0.000 claims description 10
- 241001446509 Psoralea Species 0.000 claims description 8
- 241000545442 Radix Species 0.000 claims description 8
- 239000009636 Huang Qi Substances 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 239000003826 tablet Substances 0.000 claims description 6
- 239000009490 scorpio Substances 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- -1 sublimed preparation Substances 0.000 claims description 2
- 241001421953 Eclipta <beetle> Species 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 28
- 239000008280 blood Substances 0.000 abstract description 24
- 210000004369 blood Anatomy 0.000 abstract description 22
- 210000003734 kidney Anatomy 0.000 abstract description 19
- 210000004185 liver Anatomy 0.000 abstract description 18
- 244000286838 Eclipta prostrata Species 0.000 abstract description 9
- 230000001737 promoting effect Effects 0.000 abstract description 8
- 230000017531 blood circulation Effects 0.000 abstract description 7
- 230000001105 regulatory effect Effects 0.000 abstract description 6
- 230000036737 immune function Effects 0.000 abstract description 4
- 230000004089 microcirculation Effects 0.000 abstract description 3
- 230000008901 benefit Effects 0.000 abstract description 2
- 239000000203 mixture Substances 0.000 abstract description 2
- 241000382455 Angelica sinensis Species 0.000 abstract 1
- 241000045403 Astragalus propinquus Species 0.000 abstract 1
- 241000132012 Atractylodes Species 0.000 abstract 1
- 244000124209 Crocus sativus Species 0.000 abstract 1
- 235000015655 Crocus sativus Nutrition 0.000 abstract 1
- 241001289529 Fallopia multiflora Species 0.000 abstract 1
- 244000303040 Glycyrrhiza glabra Species 0.000 abstract 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract 1
- 241000244365 Ligusticum sinense Species 0.000 abstract 1
- 241000830535 Ligustrum lucidum Species 0.000 abstract 1
- 241001248610 Ophiocordyceps sinensis Species 0.000 abstract 1
- 244000197580 Poria cocos Species 0.000 abstract 1
- 235000008599 Poria cocos Nutrition 0.000 abstract 1
- 241000239226 Scorpiones Species 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 235000006533 astragalus Nutrition 0.000 abstract 1
- 235000007215 black sesame Nutrition 0.000 abstract 1
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 abstract 1
- 235000011477 liquorice Nutrition 0.000 abstract 1
- 239000006186 oral dosage form Substances 0.000 abstract 1
- 235000013974 saffron Nutrition 0.000 abstract 1
- 239000004248 saffron Substances 0.000 abstract 1
- 238000010792 warming Methods 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 17
- 210000000952 spleen Anatomy 0.000 description 16
- 201000010099 disease Diseases 0.000 description 15
- 230000007812 deficiency Effects 0.000 description 13
- 206010025421 Macule Diseases 0.000 description 12
- 206010047642 Vitiligo Diseases 0.000 description 11
- 235000009508 confectionery Nutrition 0.000 description 10
- 208000002193 Pain Diseases 0.000 description 8
- 210000004072 lung Anatomy 0.000 description 6
- 239000002994 raw material Substances 0.000 description 6
- 206010040882 skin lesion Diseases 0.000 description 6
- 231100000444 skin lesion Toxicity 0.000 description 6
- 238000005303 weighing Methods 0.000 description 6
- 206010011224 Cough Diseases 0.000 description 5
- 206010062717 Increased upper airway secretion Diseases 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 235000019634 flavors Nutrition 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 239000012567 medical material Substances 0.000 description 5
- 208000026435 phlegm Diseases 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 208000008035 Back Pain Diseases 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 4
- 208000008930 Low Back Pain Diseases 0.000 description 4
- 208000006820 Arthralgia Diseases 0.000 description 3
- 206010007247 Carbuncle Diseases 0.000 description 3
- 206010010774 Constipation Diseases 0.000 description 3
- 208000000059 Dyspnea Diseases 0.000 description 3
- 206010013975 Dyspnoeas Diseases 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 206010033557 Palpitations Diseases 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 239000007844 bleaching agent Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 208000002173 dizziness Diseases 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 231100000614 poison Toxicity 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000002087 whitening effect Effects 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- 206010000087 Abdominal pain upper Diseases 0.000 description 2
- 201000000736 Amenorrhea Diseases 0.000 description 2
- 206010001928 Amenorrhoea Diseases 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 208000034507 Haematemesis Diseases 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 208000025747 Rheumatic disease Diseases 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 206010043376 Tetanus Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 231100000540 amenorrhea Toxicity 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 235000019658 bitter taste Nutrition 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 235000001465 calcium Nutrition 0.000 description 2
- 208000013116 chronic cough Diseases 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000003759 clinical diagnosis Methods 0.000 description 2
- 230000036461 convulsion Effects 0.000 description 2
- 230000035614 depigmentation Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 208000001848 dysentery Diseases 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 208000035861 hematochezia Diseases 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 201000007227 lymph node tuberculosis Diseases 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 201000004792 malaria Diseases 0.000 description 2
- 230000004630 mental health Effects 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 208000037920 primary disease Diseases 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000000552 rheumatic effect Effects 0.000 description 2
- 201000005404 rubella Diseases 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 230000008736 traumatic injury Effects 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 244000296912 Ageratum conyzoides Species 0.000 description 1
- 235000004405 Ageratum conyzoides Nutrition 0.000 description 1
- 206010001580 Albuminuria Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 240000002930 Alternanthera sessilis Species 0.000 description 1
- 235000015579 Alternanthera sessilis Nutrition 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 235000016535 Capraria biflora Nutrition 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 208000008967 Enuresis Diseases 0.000 description 1
- 241000201295 Euphrasia Species 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 208000031361 Hiccup Diseases 0.000 description 1
- 235000017309 Hypericum perforatum Nutrition 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 241001313288 Labia Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010024380 Leukoderma Diseases 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010033425 Pain in extremity Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000002605 anti-dotal effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 210000004905 finger nail Anatomy 0.000 description 1
- 210000003953 foreskin Anatomy 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 208000023513 hiccough Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 239000010985 leather Substances 0.000 description 1
- 208000013433 lightheadedness Diseases 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 210000003899 penis Anatomy 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 235000002378 plant sterols Nutrition 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000009666 routine test Methods 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及一种治疗白癜风的中药,该中药是将旱莲草、白术、当归、何首乌、全蝎、川穹、生地、女贞子、黄芪、冬虫夏草、茯苓、防风、藏红花、黑芝麻、补骨脂、甘草,按照常规制药方法制成各种口服剂型。本发明与现有技术相比具有温补肝肾、祛风除湿、调和气血、通经活络、活血化瘀、调节免疫功能,改善皮肤微循环的功效,对治疗和预防白癜风具有疗效确切,服用方便等突出的实质性特点和显著的进步。
Description
技术领域
本发明涉及皮肤科疾病的治疗技术领域,尤其涉及一种用于治疗白癜风疾病的中药技术领域。
背景技术
白癜风是一种常见的后天性、局限性的色素脱失性皮肤病,可发生于任何年龄,多见于儿童和青年。病损为大小不等的局限性脱色斑,边缘清楚,周围与健康皮肤交界处,皮色较浓;新发生损害周围常见有暂时性炎性晕轮、数目或单发或多发,可相互融合成片,患处毛发可变白,无任何自觉症状,日晒后损害部位有灼痒感。本病与多种自身免疫性疾病有关,如某些白癜风患者或其亲属,可合并有甲状腺功能亢进和减退、糖尿病等;某些患者的血液中发现甲状腺、胃、肾上腺组织的器官特异性抗体存在。本病常有家族史、具有家庭遗传倾向。此外,与体内铜、锌离子含量减低有关。患者多伴有汗液增多,表现温度增高,出血时间延长等症,作为白癜风疾病发生的原因多属于血虚血瘀受风者。
目前,治疗该病的方法和药物很多,但不能达到理想的效果,例如“激光”、“植皮”、“冷冻”等治疗方法,不仅疗效差,还给皮肤留下伤痕;有些药物如成药:消斑丸、去白素、白斑酊等,这些药物存在见效慢、疗程长,治愈率低和复发率高等缺点,有的药物还有过敏和轻微的中毒反应,也有的药物易引起肝、肾、脾肿大等副作用,给患者带来痛苦。
发明内容
本发明所要解决的技术问题是提供一种以消除患者的疾患,促进身心健康,同时具有患者服药方便、疗效快、无副作用的治疗白癜风的中药。
为解决上述技术问题,本发明是采用如下技术方案的:一种治疗白癜风的中药,其特殊之处是由下述重量配比的药物制成:旱莲草20-40份、白术15-35份、当归15-35份、何首乌15-35份、全蝎5-25份、川穹10-35份、生地20-40份、女贞子15-35份、黄芪20-40份、冬虫夏草1-2份、茯苓15-35份、防风10-30份、藏红花1-2份、黑芝麻20-40份、补骨脂20-40份、甘草3-10份。
为进一步解决上述技术问题,本发明所述的治疗白癜风的中药的上述重量配比的药物,其优选方案为:旱莲草25-35份、白术20-30份、当归20-30份、何首乌20-30份、全蝎10-20份、川穹15-30份、生地25-35份、女贞子20-30份、黄芪25-35份、冬虫夏草1.2-1.8份、茯苓20-30份、防风15-25份、藏红花1.2-1.8份、黑芝麻25-35份、补骨脂25-35份、甘草5-8份。
为进一步解决上述技术问题,本发明所述的治疗白癜风的中药的上述重量配比的药物,其最佳方案为:旱莲草30份、白术25份、当归25份、何首乌25份、全蝎15份、川穹22份、生地30份、女贞子25份、黄芪30份、冬虫夏草1.5份、茯苓25份、防风20份、藏红花1.5份、黑芝麻30份、补骨脂30份、甘草6份。
上述所述的中药按照中药常规制备技术制成丸剂、丹剂、散剂、片剂、膏剂、汤剂及胶囊装粉剂不同的内服药剂型。
上述所述的中药还含有药物赋形剂。
本发明所述的中药的组方原则是:滋补肝脾、益气健脾、养血活血、通经活络、活血化瘀、扶正驱邪,调节免疫功能,改善皮肤微循环,达到治疗白癜风的目的。本发明具有药物配伍得当、组方合理,其所述各味药物的功效为:
旱莲草:别名:金陵草、莲子草、旱莲子、白旱莲、猪牙草、旱莲蓬等;味甘、酸、性凉;归肝、肾经,具有补益肝肾;凉血止血之功效;主肝肾不足、头晕目眩、须发早白、吐血、咯血、衄血、便血、血痢、崩、漏、外伤出血等症。
白术:性味归经:苦、甘,温。归脾、胃经。功能主治:健脾益气,燥湿利水,止汗,安胎。用于脾虚食少,腹胀泄泻,痰饮眩悸,水肿,自汗,胎动不安。
当归:味甘辛、微苦、性温,归肝脾心经,有补血活血他、调经止痛之功效,本品与川穹配伍可以养血行滞、调经止痛等症;
何首乌:甘苦、涩,性微温,归肝、肾经,具有养血滋阴、润肠通便、截疟、祛风、解毒的功效。主治血虚头昏目眩、心悸、失眠、肝肾阴虚之腰膝酸弱;须发早白、耳鸣、遗精、肠燥便秘;久疟体虚;风疹瘙痒、疮痈、瘰疬、痔疮等疾病。
全蝎:味辛,性平;有毒。归肝经。功能主治:息风镇痉,攻毒散结,通络止痛。用于小儿惊风,抽搐痉挛,中风口歪,半身不遂,破伤风,风湿顽痹,偏正头痛,疮疡,瘰疬。
川穹:味辛、性温,有行气活血、祛风止痛的作用,用于治疗月经不调、经闭痛经、癓瘕腹痛、胸肋刺痛、跌打肿痛、头痛、风湿痹痛等症;
生地:别名:地黄、地髓、阳精、苄根,为玄参科植物。性平、味苦,中医学上以茎藤入药,功能清热解毒、活血通经,主治关节疼痛等症。
女贞子:味甘苦、性微寒、归肝肾经,具有滋补肝肾,乌发明目之功效,本品入走肝肾能益精血、乌须发、平阴火、退虚热,常用于治疗肝肾不足而致疾病;
黄芪:味:甘,微温。归肺、脾、肝、肾经。功效主治:黄芪有益气固表、敛汗固脱、托疮生肌、利水消肿之功效。用于治疗气虚乏力,中气下陷,久泻脱肛,便血崩漏,表虚自汗,痈疽难溃,久溃不敛,血虚萎黄,内热消渴,慢性肾炎,蛋白尿,糖尿病等。
冬虫夏草:味甘、平、性温,归肺、肾经,主要具有补肺益肾、止血化痰的功效,常用于治疗肾虚腰痛、阳痿遗精、肺肾两虚之久咳虚喘、劳嗽痰血,调节机体免疫功能,抑制红斑狼疮、降血糖、抗肿瘤等疾病。
茯苓:味甘、淡;性平;归心、脾、肺、肾经;功效:渗湿利水、健脾和胃、宁心安神;主治:小便不利、水肿胀满、痰饮咳逆、呕吐、脾虚食少、泄泻、心悸不安、失眠健忘、遗精白浊。
防风:味辛、甘、性微温、归膀胱、肝、脾经,具有祛风解表、胜湿止痛、止痉之功效,用于治疗外感表证、风疹瘙痒、风湿痹痛、破伤风等疾病。
藏红花:味甘、性平,具有活血化瘀、散郁开结的功效。常用于治疗胸膈痞闷、吐血、伤寒发狂、惊怖恍惚、妇女经闭,产后瘀血腹痛、跌打肿痛等疾病。
黑芝麻:为胡麻科脂麻的黑色种子,含有大量的脂肪和蛋白质,还有糖类、维生素A、维生素E、卵磷脂、钙、铁、铬等营养成分。性甘、味平,归肝、肾、大肠经。功效:补肝肾,益精血,润肠燥;主治:用于头晕眼花,耳鸣耳聋,须发早白,病后脱发,肠燥便秘。
补骨脂:味辛、性温、无毒,具有滋阴补肾之功效,常用于元阳衰损、五劳七伤、肾虚腰痛、肾气虚寒、精气不固、遗尿、脾肾虚泻、水泻久痢、妊妇腰痛、跌坠腰痛、瘀血凝滞等病症;
甘草:味甘,性平。归心、肺、脾、胃经。功能主治:补脾益气,清热解毒,祛痰止咳,缓急止痛,调和诸药。用于脾胃虚弱,倦怠乏力,心悸气短,咳嗽痰多,脘腹、四肢挛急疼痛,痈肿疮毒,缓解药物毒性、烈性。
本发明遵循中医“君臣佐使”的组方原则,全部成分来自于中国《药典》第五版收载的药物,诸药相和共具有温补肝肾,散风除湿,调和气血,通经活络、活血化瘀、扶正驱邪,调节免疫功能,改善皮肤微循环,促进皮肤色素生成,消白润肤的功效,治疗和预防白癜风、疗效确切,无毒副作用,各种中药制剂服用方便。
本发明药物临床使用结果表明,具有如下优点:
1、本发明选用的中药各组份符合中华人民共和国药品管理法之规定,利用各味中药的综合作用治疗和预防白癜风,对人体无毒无害。经小白鼠和大白鼠的急性毒性试验和蓄积性毒性试验表明被试验的动物未见任何毒性反应,经解剖观察血象、肝功能、各脏器组织形态学所见与对照组比较无差异,证明其药物安全可靠。
2、本发明所述的中药制剂无须煎煮、无苦涩感,药品中富含蛋白质、葡萄糖、葡萄糖醛酸、挥发油、果胶、果糖、有机酸、卵磷脂、维生素、氨基酸,还含皂甙、植物甾醇、钙等多种微量元素,有利于人体吸收,增强体质,且服用方便。
3、本发明所述的中药制剂不仅可有效的治疗白癜风,而且对白癜风的预防作用也非常明显,特别是通过药物之间的相互协同,增强药物各自治疗特性,通过通经活络和调节免疫功能,提高了患者身体内在的正气和身心健康及生存质量,较好的达到治愈康复效果。
下面通过临床应用例进一步说明本发明药物对治疗白癜风的治疗效果。
一、临床诊断标准:
白癜风的临床表现为:全身任何部门的皮肤均可发生,但始发于易阳光照射及磨擦损伤部,如颜面部、颈部、躯干部和四肢、口唇、阴唇、龟头及包皮内侧粘膜亦可累及。大部分白色斑对称分布,亦有部分患者白斑沿神经节段分布。皮损为局部性色素脱失斑、乳白色、自指甲至钱币大小,圆形、椭圆形或不规则形。白斑处毛发也可变白。在进展期,脱色斑向正常皮肤移行,发展较快,并有同形反应,即压力、摩擦、外伤后可形成继发白癜风。
根据皮肤白斑范围和分布可分三种类型:
1、局限性:皮损局限于一个部位,又可分为:(1)节段型:皮损按皮节分布;(2)粘膜型:仅累及粘膜。
2、泛发型:最常见,表现为皮损广泛分布于体表,可分为:
(1)寻常型:皮损散在分布于体表多处;
(2)面肢端型:皮损分布于面部和肢体远端;
(3)混合型:上述几种不同组合而成,如面肢端型+节段型等。
3、全身型:全身皮肤完全或几乎全部脱色,亦有毛发变白。
二、病例的选择
白癜风的发病率随地区、人种肤色而异,一般肤色越深的人发病率越高。我国人群中患病率约在0.1-2%,男女比例大致相等,从初生婴儿到老年均可发病,但以青少年为多。据有关资料记载:发病年龄在10-30岁内居多,占总数的62.65%,女性发病年龄较男性提早5年左右。为此,病例的选择以门疹就诊患者为全部病例。
三、疗效判定标准
在目前没有正式国家颁布的疗效判定标准之前,本发明采用的白癜风疗效判定标准(陈勤主编《中药美容保健品的研究与开发》中国医药科技出版社1999年版第228页)为:
(1)痊愈:白斑完全消失,皮肤组织病理学检查正常;
(2)显效:白斑50%以上消失,白斑消失部分组织病理学检查正常;
(3)有效:白斑消失者占原白斑面积的20-50%,或在白斑内见有较多色素岛;
(4)无效:治疗前后无变化或白斑扩大。
四、临床用药方法和治疗结果
1、临床用药方法
根据患者患病时间、病因及白斑范围和分布情况,分量用药:
服用实施例4的片剂,每次3-7克,每日2-3次,温开水送服,饭前半小时服用。两个月为一个疗程,连续服用三个疗程观察疗效。
2、治疗结果
经临床诊断治疗白癜风患者共计56例,男性26例,女性30例,年龄为12-50岁。56例患者中痊愈26例占46.4%,显效17例占30.4%,有效9例占16.1%,无效4例占7.1%,总有效率达92.9%。经过治疗后,患者皮肤白斑不同程度消退或痊愈,且病人无任何不良反应,三大常规化验及肝肾功能检测未发现任何异常。经患者痊愈回访统计,至今未见一例复发。
具体实施方式
实施例1
按下列重量份称取各中药材:旱莲草20份、白术15份、当归15份、何首乌15份、全蝎5份、川穹10份、生地20份、女贞子15份、黄芪20份、冬虫夏草1份、茯苓15份、防风10份、藏红花1份、黑芝麻20份、补骨脂20份、甘草3份。
本实施例的制备工艺为:将上述各药材原料按照常规制备丹剂的制药方法制成丹剂。
实施例2
按下列重量份称取各药材:旱莲草40份、白术35份、当归35份、何首乌35份、全蝎25份、川穹35份、生地40份、女贞子35份、黄芪40份、冬虫夏草2份、茯苓35份、防风30份、藏红花2份、黑芝麻40份、补骨脂40份、甘草10份。
本实施例的制备工艺为:将上述各药材原料按照常规制备散剂的制药方法制成袋装散剂。
实施例3
按下列重量份称取各药材:旱莲草25份、白术20份、当归20份、何首乌20份、全蝎10份、川穹15份、生地25份、女贞子20份、黄芪25份、冬虫夏草1.2份、茯苓20份、防风15份、藏红花1.2份、黑芝麻25份、补骨脂25份、甘草5份。
本实施例的制备工艺为:将上述各药材原料按照常规制备胶囊剂的制药方法制成胶囊剂。
实施例4
按下列重量份称取各药材:旱莲草35份、白术30份、当归30份、何首乌30份、全蝎20份、川穹30份、生地35份、女贞子30份、黄芪35份、冬虫夏草1.8份、茯苓30份、防风25份、藏红花1.8份、黑芝麻35份、补骨脂35份、甘草8份。
本实施例的制备工艺为:将上述各药材原料按照常规制备片剂的制药方法制成片剂,(如普通片剂、糖衣片剂、薄膜衣片剂等),并赋予常规的药物赋形剂(如淀粉、蔗糖、乳糖、硬脂酸钙、硬脂酸镁等)。
实施例5
按下列重量份称取各药材:旱莲草30份、白术25份、当归25份、何首乌25份、全蝎15份、川穹22份、生地30份、女贞子25份、黄芪30份、冬虫夏草1.5份、茯苓25份、防风20份、藏红花1.5份、黑芝麻30份、补骨脂30份、甘草6份。
本实施例的制备工艺为:将上述各药材原料按照常规制备丸剂的制药方法制成丸剂,并赋予常规的药物赋形剂。
实施例6
按下列重量份称取各药材:旱莲草28份、白术23份、当归23份、何首乌23份、全蝎15份、川穹22份、生地28份、女贞子23份、黄芪28份、冬虫夏草1.5份、茯苓23份、防风20份、藏红花1.5份、黑芝麻28份、补骨脂28份、甘草6份。
本实施例的制备工艺为:将上述各药材原料按照常规制备颗粒剂的制药方法制成颗粒剂。
Claims (5)
1.治疗白癜风的中药,其特征是由下述重量配比的药物制成:旱莲草20-40份、白术15-35份、当归15-35份、何首乌15-35份、全蝎5-25份、川穹10-35份、生地20-40份、女贞子15-35份、黄芪20-40份、冬虫夏草1-2份、茯苓15-35份、防风10-30份、藏红花1-2份、黑芝麻20-40份、补骨脂20-40份、甘草3-10份。
2.根据权利要求1所述的治疗白癜风的中药,其特征是由下述重量配比的药物制成:旱莲草25-35份、白术20-30份、当归20-30份、何首乌20-30份、全蝎10-20份、川穹15-30份、生地25-35份、女贞子20-30份、黄芪25-35份、冬虫夏草1.2-1.8份、茯苓20-30份、防风15-25份、藏红花1.2-1.8份、黑芝麻25-35份、补骨脂25-35份、甘草5-8份。
3.根据权利要求1所述的治疗白癜风的中药,其特征是由下述重量配比的药物制成:旱莲草30份、白术25份、当归25份、何首乌25份、全蝎15份、川穹22份、生地30份、女贞子25份、黄芪30份、冬虫夏草1.5份、茯苓25份、防风20份、藏红花1.5份、黑芝麻30份、补骨脂30份、甘草6份。
4.根据权利要求1至3中任一权利要求所述的治疗白癜风的中药,其特征是所述的中成药按照中药常规制备技术制成丸剂、丹剂、散剂、片剂、膏剂、汤剂及胶囊装粉剂不同的内服药剂型。
5.根据权利要求4所述的治疗白癜风的中药,其特征是所述的中成药还含有药物赋形剂。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011104036920A CN102430013A (zh) | 2011-11-29 | 2011-11-29 | 治疗白癜风的中药 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011104036920A CN102430013A (zh) | 2011-11-29 | 2011-11-29 | 治疗白癜风的中药 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102430013A true CN102430013A (zh) | 2012-05-02 |
Family
ID=45978598
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011104036920A Pending CN102430013A (zh) | 2011-11-29 | 2011-11-29 | 治疗白癜风的中药 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102430013A (zh) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104758612A (zh) * | 2015-03-30 | 2015-07-08 | 淄博夸克医药技术有限公司 | 一种用于治疗白癜风的中药 |
| CN107485649A (zh) * | 2017-09-05 | 2017-12-19 | 李太平 | 一种治疗白癜风的配方及其制作方法 |
| CN108186988A (zh) * | 2018-03-08 | 2018-06-22 | 山西忻州兴华皮肤病专科医院 | 一种治疗白癜风的中药制剂 |
| CN109846959A (zh) * | 2019-04-03 | 2019-06-07 | 安福县灵奕科技有限公司 | 一种治疗白癜风的中药组合物 |
-
2011
- 2011-11-29 CN CN2011104036920A patent/CN102430013A/zh active Pending
Non-Patent Citations (2)
| Title |
|---|
| 张作舟等: "《张作舟》", 30 April 2009, 中国中医药出版社 * |
| 罗和古等: "《经方验方巧治皮肤病》", 31 August 2007, 中国医药科技出版社 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104758612A (zh) * | 2015-03-30 | 2015-07-08 | 淄博夸克医药技术有限公司 | 一种用于治疗白癜风的中药 |
| CN107485649A (zh) * | 2017-09-05 | 2017-12-19 | 李太平 | 一种治疗白癜风的配方及其制作方法 |
| CN108186988A (zh) * | 2018-03-08 | 2018-06-22 | 山西忻州兴华皮肤病专科医院 | 一种治疗白癜风的中药制剂 |
| CN109846959A (zh) * | 2019-04-03 | 2019-06-07 | 安福县灵奕科技有限公司 | 一种治疗白癜风的中药组合物 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102416079A (zh) | 一种治疗白癜风的中成药 | |
| CN103251867A (zh) | 一种治疗糖尿病的中药复方药物及其制备方法 | |
| CN102362950A (zh) | 一种治疗白癜风的中药 | |
| CN103520572A (zh) | 一种用于治疗特应性皮炎的中药组合物及其制备方法 | |
| CN100496585C (zh) | 一种治疗黄褐斑的中药制剂 | |
| CN105327205A (zh) | 一种治疗甲状腺癌的中药制剂 | |
| CN104352776A (zh) | 一种治疗月经过少致不孕的中药制剂及其制备方法 | |
| CN103432559A (zh) | 一种治疗血滞型月经减少及痛经的中药组合物及其制备方法和用途 | |
| CN102430013A (zh) | 治疗白癜风的中药 | |
| CN101897933B (zh) | 一种治疗白癜风的中成药 | |
| CN102727648A (zh) | 一种治疗白癜风的中药组合物 | |
| CN102430097A (zh) | 一种治疗白癜风的中药 | |
| CN103977281A (zh) | 一种治疗女性内分泌失调的中药组合物及其制备方法 | |
| CN102423433A (zh) | 一种用于治疗银屑病的中药混合物 | |
| CN104800771A (zh) | 一种用于儿童夜惊症的中药制剂及其制备方法 | |
| CN104906430A (zh) | 一种治疗干眼症的中药制剂及其制备方法 | |
| CN104906507A (zh) | 一种降低血压、调理体质的中药组合物 | |
| CN104257778A (zh) | 一种治疗风湿性关节炎的中药 | |
| CN103690869B (zh) | 治疗肠易激综合征的中药及其制备方法 | |
| CN102406865A (zh) | 一种治疗银屑病的中药组合物 | |
| CN102406893A (zh) | 一种治疗银屑病的中成药 | |
| CN102579895B (zh) | 一种治疗银屑病的中药组合物 | |
| CN101129832A (zh) | 一种治疗糖尿病尿路感染的中药组合物 | |
| CN105125911A (zh) | 一种用于调治前列腺增生的中药组合物及其制备方法 | |
| CN105106634A (zh) | 一种治疗急性阑尾炎的中药制剂及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20120502 |
|
| RJ01 | Rejection of invention patent application after publication |